A new randomized clinical trial found no added benefit from combining bicalutamide with minoxidil in the treatment of female pattern hair loss, contrasting with findings from previous retrospective studies and noting that further research on antiandrogen therapy is needed.
Eli Lilly's JAK inhibitor demonstrated 80% scalp hair regrowth in 42.4% of adolescents with severe alopecia areata after just 36 weeks of treatment, outperforming placebo in the Phase 3 BRAVE-AA-PEDS trial.
Individuals with androgenetic alopecia face an increased risk of depression, with an odds ratio of 1.015, according to a new Mendelian randomization study.